BIF acquires shares in Orbis Diagnostics Limited

Booster Innovation Fund acquires share in Orbis Diagnostics Limited 20 May 2022 Booster Innovation Fund adds Orbis Diagnostics to its investment portfolio Booster is pleased to announce the addition of Orbis Diagnostics to the Booster Innovation Fund (BIF) portfolio, Orbis Diagnostics (formed in 2016) operates in the life sciences and medical technologies sector. It specialises in the development of point of care diagnostics. It's 'lab in a box' testing platform uses its microfluidic disk to miniaturise and automate accurate lab testing for use at points of need. The company is classified as early expansion stage. BIF will make a cash investment of $250,000. Following this transaction (and issue of additional units to fund the purchase), Orbis Diagnostics will represent 3% of BIF's investment portfolio of 21 companies, and with a net asset value of over $8.1m. Investors can continue to purchase units in BIF on the NZX or can subscribe for units in the fund as part of the process described in the fund's Product Disclosure Statement (PDS) that is available at www.booster.co.nz For further information regarding BIF visit https://www.booster.co.nz/booster-investments/booster-innovation-fund.aspx For more information, please contact: Gary Scott Company Secretary Booster Investment Management Limited 04 8944300 About Booster Booster Investment Management Limited (Booster) is the manager and issuer of the Fund, and part of the Booster Group which has been helping New Zealanders save since 1998. The group currently administers superannuation and investment funds of over $5 billion on behalf of more than 170,000 New Zealanders. BIF is a managed investment fund that invests in early-stage companies founded on intellectual property originated or developed in New Zealand. For more information, including a copy of the Product Disclosure Statement, please visit www.booster.co.nz End CA:00392393 For:BIF Type:TRANSACT Time:2022-05-20 10:34:44